Literature DB >> 26066920

Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011.

Margot Kuo1, Naveed Z Janjua1, Ann N Burchell1, Jane A Buxton1, Mel Krajden1, Mark Gilbert1.   

Abstract

OBJECTIVES: We estimated HCV incidence among individuals who repeatedly underwent anti-HCV testing.
METHODS: We studied HCV-negative individuals who had at least 2 tests between April 1992 and September 2012 in British Columbia, Canada. We calculated incidence as the number of new infections per 100 person-years at risk.
RESULTS: From 1992 to 2012, 323 598 individuals who persistently tested negative and 7490 HCV seroconverters contributed 1 774 262 person-years of observation time. Incidence rates ranged from 2.66 infections per 100 person-years (95% confidence interval [CI] = 2.07, 3.35) in 1993 to 0.25 infections per 100 person-years (95% CI = 0.21, 0.29) in 2011. Rates declined sharply in the 1990s and declined more gradually in the 2000s. Incidence declined with age; highest incidence rates were among those aged 15 to 24 years. Incidence among male repeat testers exceeded that of female repeat testers across all years, although the gap narrowed over time.
CONCLUSIONS: Addictions treatment, harm reduction, prevention education, and novel initiatives to remove barriers in health infrastructure need to be intensified for those who inject drugs, particularly men and younger persons.

Entities:  

Mesh:

Year:  2015        PMID: 26066920      PMCID: PMC4504305          DOI: 10.2105/AJPH.2015.302591

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  22 in total

1.  Risk behaviors and HIV incidence among repeat testers at publicly funded HIV testing sites in San Francisco.

Authors:  Susan E Fernyak; Kimberly Page-Shafer; Timothy A Kellogg; William McFarland; Mitchell H Katz
Journal:  J Acquir Immune Defic Syndr       Date:  2002-09-01       Impact factor: 3.731

2.  Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

Authors:  Jason Grebely; Gail V Matthews; Andrew R Lloyd; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2013-05-31       Impact factor: 9.079

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

4.  Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008.

Authors:  Bryce D Smith; Geoff A Beckett; Anthony Yartel; Deborah Holtzman; Nita Patel; John W Ward
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

5.  Test uptake and case detection of syphilis, HIV, and hepatitis C among women undergoing prenatal screening in British Columbia, 2007 to 2011.

Authors:  Margot Kuo; Deborah M Money; Maria Alvarez; Jane A Buxton; Mel Krajden; Richard T Lester; Gina Ogilvie; Mark Gilbert
Journal:  J Obstet Gynaecol Can       Date:  2014-06

6.  Magnitude and determinants of first-time and repeat testing among individuals with newly diagnosed HIV infection between 2000 and 2001 in Alberta, Canada: results from population-based laboratory surveillance.

Authors:  Gayatri C Jayaraman; Katherine R Bush; Bonita Lee; Ameeta E Singh; Jutta K Preiksaitis
Journal:  J Acquir Immune Defic Syndr       Date:  2004-12-15       Impact factor: 3.731

7.  Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?

Authors:  Anneke S de Vos; Jannie J van der Helm; Amy Matser; Maria Prins; Mirjam E E Kretzschmar
Journal:  Addiction       Date:  2013-03-13       Impact factor: 6.526

Review 8.  Global estimates of prevalence of HCV infection among injecting drug users.

Authors:  Carmen Aceijas; Tim Rhodes
Journal:  Int J Drug Policy       Date:  2007-08-07

9.  HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand.

Authors:  D Kitayaporn; C Uneklabh; B G Weniger; P Lohsomboon; J Kaewkungwal; W M Morgan; T Uneklabh
Journal:  AIDS       Date:  1994-10       Impact factor: 4.177

10.  The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007.

Authors:  Jannie J van der Helm; Maria Prins; Julia del Amo; Heiner C Bucher; Geneviève Chêne; Maria Dorrucci; John Gill; Osamah Hamouda; Mette Sannes; Kholoud Porter; Ronald B Geskus
Journal:  AIDS       Date:  2011-05-15       Impact factor: 4.177

View more
  8 in total

Review 1.  Contextualizing Canada's hepatitis C virus epidemic.

Authors:  Mel Krajden; Darrel Cook; Naveed Z Janjua
Journal:  Can Liver J       Date:  2018-12-25

2.  "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.

Authors:  Trevor Goodyear; Helen Brown; Annette J Browne; Peter Hoong; Lianping Ti; Rod Knight
Journal:  Int J Drug Policy       Date:  2021-04-23

3.  Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort.

Authors:  Naveed Zafar Janjua; Amanda Yu; Margot Kuo; Maria Alvarez; Darrel Cook; Jason Wong; Mark W Tyndall; Mel Krajden
Journal:  BMC Infect Dis       Date:  2016-07-19       Impact factor: 3.090

4.  The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).

Authors:  Naveed Z Janjua; Margot Kuo; Amanda Yu; Maria Alvarez; Stanley Wong; Darrel Cook; Jason Wong; Jason Grebely; Zahid A Butt; Hasina Samji; Alnoor Ramji; Mark Tyndall; Mel Krajden
Journal:  EBioMedicine       Date:  2016-08-25       Impact factor: 8.143

5.  A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.

Authors:  Zahid Ahmad Butt; Nabin Shrestha; Stanley Wong; Margot Kuo; Dionne Gesink; Mark Gilbert; Jason Wong; Amanda Yu; Maria Alvarez; Hasina Samji; Jane A Buxton; James C Johnston; Victoria J Cook; David Roth; Theodora Consolacion; Michelle Murti; Travis S Hottes; Gina Ogilvie; Robert Balshaw; Mark W Tyndall; Mel Krajden; Naveed Z Janjua
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

6.  Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.

Authors:  D C Des Jarlais; H L F Cooper; K Arasteh; J Feelemyer; C McKnight; Z Ross
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

7.  Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion.

Authors:  James Wilton; Stanley Wong; Roy Purssell; Younathan Abdia; Mei Chong; Mohammad Ehsanul Karim; Aaron MacInnes; Sofia R Bartlett; Rob F Balshaw; Tara Gomes; Amanda Yu; Maria Alvarez; Richard C Dart; Mel Krajden; Jane A Buxton; Naveed Z Janjua
Journal:  JAMA Netw Open       Date:  2022-01-04

8.  Hepatitis C virus testing in a clinical HIV cohort in Ontario, Canada, 2000 to 2015.

Authors:  Nasheed Moqueet; Ramandip Grewal; Tony Mazzulli; Curtis Cooper; Sandra L Gardner; Irving E Salit; Abigail Kroch; Ann N Burchell
Journal:  Health Sci Rep       Date:  2021-09-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.